Trials / Completed
CompletedNCT03363269
Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- IlDong Pharmaceutical Co Ltd · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy of ID1201 in patients with mild Alzheimer's disease
Detailed description
ID1201 is a fruit extract of Melia toosendan. ID1201 alleviates Alzheimer's disease-type pathologies and cognitive deficit through the various actions of its effective components such as α-secretase activation followed to Aβ reduction, RAGE inhibition, neuro-protection, and anti-inflammatory activities.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ID1201 |
Timeline
- Start date
- 2016-04-12
- Primary completion
- 2018-12-31
- Completion
- 2019-04-17
- First posted
- 2017-12-06
- Last updated
- 2019-06-04
Locations
20 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03363269. Inclusion in this directory is not an endorsement.